



COVID-19 Pandemic Symposium

Session/ Tuesday April 26th

Chairman: Pedro Mas. PhD & Gabriel A. Picone PhD

Session: Epidemiology of COVID-19 (Epidemic control, management and pandemic preparedness)					
		Speakers	Institution	Country	Modality
10:30	10:45	Francisco Duran. "Epidemiology of the COVID-19 in Cuba"	National Director of Epidemiology, Ministry of Public Health	Cuba	Face to face
10:50	11:05	María Guadalupe Guzman. "Emergence and evolution of SARS-CoV-2 genetic variants during the Cuban epidemic"	Diagnostic and Reference Research Center (CIDR) of the Institute of Tropical Medicine "Pedro Kouri" IPK	Cuba	Face to face
11:10	11:25	Gabriel A. Picone. "Excess mortality due to COVID19 in the United States and Vaccines in the United States"	University of South Florida	USA	Face to face
11:30	11:45	Pedro Mas-Bermejo. "Effectiveness in preventing severe disease and mortality from COVID19 disease in Havana, Cuba. Cohort study"	Institute of Tropical Medicine "Pedro Kouri" IPK	Cuba	Face to face
11:50	12:05	John De Pasquale. "Epidemiology and Control of Covid-19 in Alaska, 2020 – 2022"	Coalition of Concerned Medical Professionals (CCMP)	USA	Face to face
12:10	12:25	Raúl Guinovart Díaz. "Social impact of scientific modeling in the multidisciplinary confrontation with COVID-19 in Cuba"	Faculty of Mathematics and Computing. Havana University	Cuba	Face to face
12:30	12:45	Elisabeth L. Stevens. "Pandemic Mitigation in US: Successes and Failures; Observations From two US states – Alaska and New York, 2020 – 2022"	Coalition of Concerned Medical Professionals (CCMP)	USA	Face to face
12:50	13:05	Ileana Morales. "Cuban vaccination strategy"	National Director of Science and Research. Ministry of Public Health	Cuba	Face to face

Lunch

Chairman: Mark Emalfarb, PhD & Gerardo Guillén. PhD

Session: Vaccines (1)					
		Speakers	Institution	Country	Modality
14:30	15:00	Logunov Denis Yurievich. "Experience of Sputnik V (Gam-Covid-Vac) vaccine development during COVID-19 pandemia"	Co-director, N.F. Gamaleya NRCEM	Russia	Virtual
15:05	15:35	Vicente Verez. "Design and evaluation of SOBERANAs vaccines: RBD-multiepitopic presentation as alternative for improving immune response"	General Director, Finlay Vaccine Institute	Cuba	Face to face

15:40	16:10	Verena Muzio. " Clinical development of Abdala, the first Latin American Covid-19 vaccine "	Director of Clinical Research, Center for Genetic Engineering and Biotechnology (CIGB)	Cuba	Face to face
16.10	16.20	Break			
16:30	17:00	Gerardo Guillén. "Hepatitis B nucleocapsid particle as immunopotentiator of innate and adaptive immunity for nasal vaccines CIGB 2020 and Mambisa against COVID-19"	Center for Genetic Engineering and Biotechnology (CIGB)	Cuba	Face to face
17:05	17:35	Mark Emalfarb. "Thermophilic Filamentous Fungus, Thermotheomyces heterothallica, C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted With Aldydrogel®85 Protects K18-hACE2 Mice Against Lethal Virus Challenge"	Dyadic International Inc.	USA	Face to face

Session/Wednesday April 27th

Chairman: Eleanor Fish . PhD & Iraldo Bello. PhD

Session: Interferons					
		Speakers	Institution	Country	Modality
9:00	9:25	Eleanor N. Fish. "Global virus outbreaks: interferons as first line therapeutics"	The University Health Network	Canada	Face to face
9:30	9:50	Iraldo Bello. "HeberFERON in the treatment of COVID-19. Impact in early and worsen disease"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
9:55	10:15	Ana Aguilera. "New formulation (Nasalferon) that contains IFN hum-Rec for the prophylactic treatment of COVID-19"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
10:20	10:45	Dania Vazquez Blomquist. "The new nasal formulation of IFN α 2b, Nasalferon, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood."	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
10:50	11:10	Howard Young "Interferon-gamma: When a good cytokine goes bad"	National Cancer Institute at Frederick	USA	Virtual
11:15	11:30	Coffee Break			

Chairman: María del Carmen Domínguez PhD & Raúl Herrera PhD

Session: Therapeutics and immunomodulators					
		Speakers	Institution	Country	Modality
11:30	11:50	Mayra Ramos-Suzarte. "Itolizumab in the treatment of patients with COVID-19: Cuban experience"	Center for Molecular Immunology	Cuba	Face to face
11:55	12:15	Tania Crombet. "Blocking EGFR with nimotuzumab: A novel strategy for COVID-19 treatment"	Center for Molecular Immunology	Cuba	Face to face
12:20	12:40	Mary Carmen Reyes. "Use of Biomodulina T [®] from a preventive scenario to confront COVID19 in Cuba"	Bioprocessing Center	Cuba	Face to face
12:45	13:05	María del Carmen Domínguez-Horta. "Jusvinza, a peptide derived from human heat-shock protein 60, for treatment of hyperinflammation in COVID-19 patients"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
13:10	13:30	Raúl Herrera. "COVID-19 and kidney: risk, damage and sequel"	Nefrology Institute	Cuba	Face to face
13:35	14:30	Lunch			

Chairman: MSc. Olga Lidia Jacobo Casanueva (Director, CECMED) & Dr. Alejandro Svarch (Federal Commissioner, COFEPRIS)

Panel: Strategies and regulatory actions of the Cuban Regulatory Authority for the authorization of Cuban medicines and new technologies to confront Covid-19					
Moderator: Ismary Alfonso Orta PhD					
		Panelists:	Institution	Country	Modality
14:30 - 15:30		1. Dr. Mario Cesar Muñiz. Head of the Department of Medical Equipment and Devices. 2. MSc. Laura Rivas Saavedra. Diagnostic Section Specialist. 3. MSc. Violeta Perez Rodriguez. Head of Biologicals section. Department of Medicines and Biologicals. 4. Dr. Liset Báez Cubas. Head of Preclinical and Clinical Section. Department of Medicines and Biologicals.	Cuban National Regulatory Authority (CECMED)	Cuba	Face to face

Chairman: Dagmar García-Rivera. PhD & Arjan Willen Griffioen. PhD

Session: Vaccines (2)					
		Speakers	Institution	Country	Modality
15:30	15:45	Arjan Willen Griffioen. "Vaccination with a bacterial peptide conjugated to SARS-CoV-2 RBD accelerates	Free University of Amsterdam	Netherlands	Face to face

		immunity and protects against COVID-19”			
15:50	16:05	Francisco Hernández-Bernal. “A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study)”	Center for Genetic Engineering and Biotechnology (CIGB)	Cuba	Face to face
16:10	16:25	Françoise Paquet. “Structural biology for vaccine development: the example of SOBERANA vaccines”	Centre de Biophysique Moléculaire	France	Face to face
16:30	16:45	Maria Eugenia Toledo Romani. “Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination”	Institute of Tropical Medicine “Pedro Kouri” IPK	Cuba	Face to face
16:50	17:05	Dagmar García-Rivera. “Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children”	Finlay Vaccine Institute	Cuba	Face to face
17:10	17:25	Rinaldo Puga-Gómez. “Vaccination of convalescent children: Open label phase I/II clinical trial with a single doses of SOBERANA Plus”	Pediatric Hospital “Juan Manuel Marquez”, Central Clinic “Cira García”	Cuba	Face to face
17:30	17:45	Zurina Cinza. “Immunogenicity and Safety assessment of a SARS-CoV-2 recombinant spike protein vaccine (Abdala) in paediatric ages 3 to 18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)”	Center for Genetic Engineering and Biotechnology	Cuba	Face to face

Session/Thursday April 28th

Chairman: Consuelo Macías. PhD & Celia Fernández. PhD

Session: Antivirals and therapy					
		Speakers	Institution	Country	Modality
09:00	09:10	Consuelo Macías. "Treatment of lung lesions with autologous stem cells in patients recovered from COVID-19"	Institute of Hematology and Immunology	Cuba	Face to face
09:15	9:25	Celia Fernández. "CIGB-460: A novel peptide-based drug candidate to inhibit coronavirus infections"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
9:30	9:40	Johann Perdomo Delgado. "Natural and Traditional Medicine to fight COVID-19 in Cuba: the case of Ozone Therapy"	Ministry of Public Health	Cuba	Face to face
9:45	9:55	Hugo Nodarse Cuni. "Use of interferon alfa in patients with COVID-19. The Cuban experience"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face

Chairman: Francisco Hernández-Bernal. PhD & Rolando Ochoa Azze. PhD

Session: Vaccines (3)					
10:00	10:10	Odalys Bravo Téllez. "Hitos de la estrategia cubana de vacunación anti-Covid-19"	Ministry of Public Health	Cuba	Face to face
10:15	10:25	Mislady Rodríguez Ortega. "Effectiveness of the Soberana vaccine in health workers of nine sentinel hospitals, Havana, 2021"	Institute of Tropical Medicine "Pedro Kouri" IPK	Cuba	Face to face
10:30	10:40	Rolando Ochoa Azze. "Vaccination with SOBERANA Plus in COVID-19 convalescents: safe and efficient strategy to prevent severe reinfection"	Finlay Vaccine Institute	Cuba	Face to face
10:45	10:55	Yenima Martín Bauta. "Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
11:00	11:15	Coffee Break			
11:15	11:35	Pierre A. Morgon. "Vaccines Technologies driving Acceptability, Affordability and Localization"	MRGN Advisors	Switzerland	Virtual
11:40	11:50	Julio D. Fernández Águila. "A phase II, double-blind, randomized and non-inferiority clinical trial of SOBERANA 01 and SOBERANA 02 vaccines in heterologous schedule with SOBERANA Plus as a booster vaccine"	Finlay Vaccine Institute	Cuba	Face to face
11:55	12:05	Nibaldo Luis González Sosa. "SARS-CoV-2 infectivity in Golden Syrian Hamster as a model for immunogenicity and efficacy assays of Cuban biomolecules and vaccine candidates against COVID-19".	Civil Defense Scientific Research Center	Cuba	Face to face
12:10	12:20	Valdes-Balbin Yury. "SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity: preclinical results of a vaccine candidate SOBERANA 02"	Finlay Vaccine Institute	Cuba	Face to face
12:25	12:35	Reynaldo Oliva-Hernández. "Efficacy and Preclinical Safety of vaccine candidates to SARS-CoV-2 (SOBERANA® Vaccines)"	Finlay Vaccine Institute	Cuba	Face to face
12:40	12:50	Thailín Lao. "Chimeric antigen produced in HEK-293 cells, based on SARS-CoV2 nucleoprotein fused to the extracellular domain of human CD154, induced high immunogenicity in mice and non-human primates"	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
12:55	13:05	Ingrid Rodríguez-Alonso. "Abdala vaccine against SARS-CoV-2 induces functional antibodies in	Center for Genetic Engineering and Biotechnology	Cuba	Face to face

		rats and cynomolgus monkeys”			
13:10	13:20	Rodríguez Noda L. “A single dose of SARS-CoV-2 dimeric-RBD recombinant (Soberana Plus) boost the immunogenicity of the inactivated BBIBP-CorV vaccine: from preclinical to clinical”	Finlay Vaccine Institute	Cuba	Face to face
13:25	13:35	Elena Zavyalova. DNA aptamers for virus detection	Chemistry Department, Moscow State University	Russia	Virtual
13:40	14:30	Lunch			
Chairman: MSc. Amaylid Arteaga García & Belkys Maria Galindo Santana. PhD					
		Session: Vaccine (4)			
		Speakers	Institution	Country	Modality
14:30	14:40	Amaylid Arteaga García. “The National Coordinating Center for Clinical Trials in the fight against COVID-19: main contributions”	Clinical Trials Coordination Center	Cuba	Face to face
14:45	14:55	Belkys Maria Galindo Santana. “Surveillance of adverse events with the application of the Abdala vaccine against COVID-19”	Institute of Tropical Medicine “Pedro Kouri” IPK	Cuba	Face to face
15:00	15:10	Lizet Sanchez Valdes. “Clinical severity of COVID-19 patients during the omicron wave in Cuba”	Center of Molecular Immunology	Cuba	Face to face
15:15	15:25	Kenia Almenares Rodríguez. “Impact and effectiveness of the Abdala vaccine against symptomatic disease and mortality by COVID-19. Matanzas, 2021”	National School of Public Health	Cuba	Face to face
15:30	15:40	Mery Martínez Cabrera. “Surveillance of adverse events during the anti SARS-COV-2 vaccination campaign in Cuba with SOBERANA® 02 y SOBERANA® Plus”	Finlay Vaccine Institute	Cuba	Face to face
15:45	15:55	Gilda Lemos. “Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays”	Center for Genetic Engineering and Biotechnology	Cuba	Face to face
16:00	16:15	Coffee Break			
Chairman: Jorge Gulín-González. PhD & Nivaldo Luis González Sosa					
		Session: Fundamental research			
16:15	16:35	Stefan Pöhlmann. “The 3As of SARS-CoV-2 entry into cells: ACE2, activators and antibodies”	Faculty of Biology and Psychology, Georg-August-University Göttingen	Germany	Face to face
16:40	16:50	Jorge Gulín-González. “A Computational Approach to Finding SEIR Model Parameters that Best Explain Infected and Recovered Time Series for SARS-CoV-2”	University of Informatics Sciences	Cuba	Face to face
16:55	17:05	Ivette Orosa-Vázquez. “Longitudinal study of the immune response generated against SARS-CoV-2 infection in Cuban COVID-19 recovered patients”	Center of Molecular Immunology	Cuba	Face to face
17:10	17:20	Patricia Lorenzo-Luaces Alvarez. “Propensity score matched cohort to comparison of severe COVID-19 patients treated or not with Nimotuzumab”	Center of Molecular Immunology	Cuba	Face to face
17:25	17:35	Vianed Marsán Suárez. “Biomarkers of sequela in adult patients convalescing from COVID-19”	Institute of Hematology and Immunology	Cuba	Face to face
17:40	17:50	Bárbara Torres Vives. “Changes in immune response according to clinical severity in COVID-19 convalescent individuals and uninfected exposed relatives”	National Center of Medical Genetics	Cuba	Face to face

9:00 – 13:00 Poster Sessions

Posters Board 1 (COVID-19 Symposium/Morning Session/Room 3/Therapy) Friday April 29th

Chairman: Dr. Dania Vazquez Blomquist and Dr. Héctor José Pérez Hernández

9:00	9:10	1. Intranasal administration of recombinant human interferon alfa-2b as prophylaxis against SARS-CoV-2 infection (OLIVO Study).	Joel M. Quintana Guerra. CIGB
9:10	9:20	2. Characteristics of the registered Cuban clinical research for the confrontation with COVID 19.	Ania Torres Pombert. CECNCEC
9:20	9:30	3. Interference of CK2-mediated signaling to weaken/attack SARS-CoV-2 infection: a computational biology approach.	Jamilet Miranda. CIGB
9:30	9:40	4. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Betacoronavirus Infections.	Ailyn C. Ramón. CIGB
9:40	9:50	5. Jusvinza, a peptide with activity against hyperinflammation process induced by SARS-CoV-2 is safe in Macaca fascicularis monkeys.	Jorge Castro. CIGB
9:50	10:00	6. Understanding the impact of Cuban immunotherapy protocols during Covid-19 disease: contributions from mathematical modeling.	Karina García. CIM
10:00	10:10	7. Active Pharmaco-Surveillance Study of HeberFERON® in Basal Cell Carcinoma and COVID-19.	María Mercedes Vázquez Marcos. CIGB
10:10	10:20	8. Early Treatment with a Peptide Derived from the Human Heat-Shock 60 Protein Avoids Progression to Severe Stages of COVID-19.	Julio E Baldomero Hernández. CIGB
10:20	10:30	9. Informed consent in medical activity to confront COVID-19.	Laura Barrero Viera. CENATOX
10:30	10:40	10. Rational for the use of CIMAVAX-EGF® in post-COVID-19 pulmonary sequelae.	Héctor José Pérez Hernández. Saturnino Lora Provincial Hospital, Santiago de Cuba
10:40	10:50	11. Epidermal growth factor in patients hospitalized by mild-moderate covid-19: series of cases.	Héctor José Pérez Hernández. Saturnino Lora Provincial Hospital, Santiago de Cuba
10:50	11:10	Cofee Break	
11:10	11:20	12. Adverse reactions associated with recombinant interferon alfa 2b in suspected and confirmed COVID-19 patients.	Lisvan Yassel Cala Rosabal. University Polyclinic Dr. Gustavo Aldereguía Lima, Las Tunas
11:20	11:30	13. Therapeutic response of HeberFERON in patients with basal cell carcinoma and its association with COVID 19, in Jagüey Grande, Matanzas. 2020-2021.	Sandra Cordovés Quintana. Jagüey Grande Polyclinic
11:30	11:40	14. Lithium salts as a treatment for COVID-19: preclinical results.	Ormany Soriano Torres. Medical School "Victoria de Girón"
11:40	11:50	15. Characterization by mass spectrometry of the RBD obtained in different expression systems.	Ivan Andújar. CIGB
11:50	12:00	16. Systematization of experiences in confronting COVID-19 in different Cuban municipalities, 2020-2021	Pedro Luis Véliz Martínez. National Council of Health Scientific Societies
12:00	12:10	17. Development of a quantitative test for detection of alpha IFN in plasma samples.	Giselle Freyre. CIGB
12:10	12:20	18. A flow cytometry gating strategy for profiling CD4+CD25+/highCD127-/low regulatory T cells.	Ricardo Ulises Martínez. CIGB
12:20	12:30	19. Assessment of immunological response in nasal lining, saliva and serum samples in COVID's convalescent individuals immunized with a single dose of Mambisa oral.	Yahima Chacón. CIGB
12:30	12:40	20. Strategy for developing vaccines against COVID-19 based on dimeric RBD.	Yanet Climent. Finlay vaccine Institute
12:40	12:50	21. SOBERANA 02 vaccine: strategy for developing the unique conjugate vaccine against SARS-CoV-2.	Sonsire Fernández Castillo. Finlay Vaccine Institute
12:50	13:00	22. Clinical evolution and inflammatory markers of severe and critical obstetric patients with COVID-19,	Anadys Beatriz Segura Fernández. Central Military Hospital "Luis

		treated with Jusvinza.	Díaz Soto"
13:00	14:30	Lunch	

Posters Board 2 (COVID-19 Symposium/Morning Session/Room 3/ Prophylaxis and Vaccines) Friday April 29th

Chairman: Dr. Diógenes Quintana Vazquez and Dr. Mislady Rodríguez Ortega

9:00	9:10	1. Program and toxicological preclinical designs of the Abdala vaccine	Lizet Aldana Velazco. CIGB
9:10	9:20	2. Evaluation of cellular response in individuals vaccinated with Abdala using the ELISPOT technique.	Sheila Chavez. CIGB
9:20	9:30	3. Potentially neutralizing anti-SARS-CoV-2 antibodies in human milk following vaccination with Abdala.	Maylin Pérez Bernal. CIGB
9:30	9:40	4. Characterization of the immune response of workers at the Finlay Vaccine Institute immunized with SOBERANA 02/SOBERANA PLUS.	Samantha Fernández González. Finlay Vaccine Institute
9:40	9:50	5. Immunogenicity of the vaccine formulations RBDd/OMV/Al(OH) ₃ and RBDd/Al(OH) ₃ against SARS-CoV-2.	Claudia Labrada Regalado. Finlay Vaccine Institute
9:50	10:00	6. Recombinant human interferon alfa-2b administered in nasal drops for prophylaxis of SARS-CoV-2 infection in populations at risk.	Hugo Nodarse Cuni. CIGB
10:00	10:10	7. Report on the use of the Abdala vaccine as a booster of natural infection and the primary vaccination schedule with different vaccines against SARS-CoV-2	Celia Crespo Oliva. CIGB
10:10	10:20	8. Effect of the intranasal dose of HeberNasvac (CIGB2020) on the oropharyngeal expression of TLRs and other genes of the innate immune system: dose-escalating pilot study I	Jorge Aguiar Santiago. CIGB
10:20	10:30	9. Evaluation of drop and spray devices through intranasal administration of HeberNasvac (CIGB2020) and innate immunity effects on oro-nasopharyngeal tonsils of healthy volunteers compared to Nasalferon and a control group. Pilot study II	Diógenes Quintana Vazquez. CIGB
10:30	10:40	10. Antiviral and innate immune responses elicited by Nasalferon administration: dose-escalating pilot study I.	Yssel Mendoza Marí. CIGB
10:40	10:50	11. SOBERANA Vaccines in the pediatric population. Vaccination experience of the Molecular Immunology Center.	Giselle Saurez Martínez. CIM
10:50	11:10	Cofee Break	
11:10	11:20	12. Chimeric antigen by the fusion of SARS-CoV-2 Receptor Binding Domain with the extracellular domain of human CD154: a promising improved vaccine candidate.	Ileanet Ávalos. CIGB
11:20	11:30	13. Nasalferon early post marketing surveillance in health contingencies for COVID-19.	María Mercedes Vázquez Marcos. CIGB
11:30	11:40	14. Adverse events reported in the Phase I of Soberana 01 clinical trial against COVID-19.	Yunior González Freyre. CENATOX
11:40	11:50	15. Selection of volunteers in the MAMBISA vaccine candidate clinical trial against COVID-19.	Lilia Beatriz Rosales Gil. CENATOX
11:50	12:00	16. Evaluation of the Data Monitoring Committees in the clinical trials of Cuban vaccines against COVID-19.	Sonia Pérez Rodríguez. CENATOX
12:00	12:10	17. Cuban vaccines against Covid - 19: Impact of the procedure "Creation and operation of the Data Monitoring Committee in clinical trials".	Héctor Lázaro Lara Fernández. CENCEC
12:10	12:20	18. Optimal viral antigen/carrier protein ratio for the active ingredient of the anti-SARS-CoV-2 conjugate vaccine: SOBERANA 02.	Lauren M. Quintero Moreno. Finlay Vaccine Institute

12:20	12:30	19. Design of RBD lipoproteins as active component of multivalent formulations against SARS-CoV-2 virus.	Lugo Calas Aloima. Finlay Vaccine Institute
12:30	12:40	20. Physicochemical characterization of the SARS-CoV-2 receptor binding domain (RBD) protein and intermediates of the Active Pharmaceutical Ingredient of the SOBERANA 02 conjugate vaccine.	Raine Garrido Arteaga. Finlay Vaccine Institute
12:40	12:50	21. Physicochemical characterization of the vaccine candidate SOBERANA 01 through chromatographic, electrophoretic and light scattering methods.	Bárbara Baró Bicet. Finlay Vaccine Institute
12:50	13:00	22.	
13:00	14:30	Lunch	

Posters Board 3 (COVID-19 Symposium/Morning Session/Room 3/ Diagnostic and Analytical Tests) Friday April 29th

Chairman: Dr. Irinia Valdivia Alvarez and Dr. Otto Cruz Sui

9:00	9:10	1. Obtaining inactivated SARS-CoV-2 antigen for use in the evaluation of the cellular immune response.	Martha Dubed Echevarría. CICDC
9:10	9:20	2. A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies.	Franciscary Pi-Estopiñan. CIM
9:20	9:30	3. Different methods based on the use of anti-RBD monoclonal antibodies (MABs) for protein identity in IFAs and Soberana 01, Soberana 02 and Soberana Plus vaccines at the Finlay Vaccine Institute.	Yanedis Santoya Tamayo. Finlay Vaccine Institute
9:30	9:40	4. Design and standardization of a Dot blot identity method for SOBERANA 01, SOBERANA 02 and SOBERANA plus vaccines.	Yaimara Rodríguez Hernández. Finlay Vaccine Institute
9:40	9:50	5. Conjugation of two anti-RBD monoclonal antibodies of the SARS-CoV-2 virus and its applicability in sandwich ELISA for the quantification of protein in APIs and in the SOBERANA 01, SOBERANA 02, SOBERANA Plus vaccines of the Finlay Vaccine Institute.	Raquel de la Caridad Mujica La Fe. Finlay Vaccine Institute
9:50	10:00	6. Murine monoclonal antibodies against SARS-CoV-2 nucleocapsid protein for COVID-19 diagnosis and research.	Omar R. Blanco. CIGB
10:00	10:10	7. Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials.	Yeosvany Cabrera. CIGB
10:10	10:20	8. Estrategias para la ejecución de ensayos clínicos de Soberana 02 y Soberana Plus en Plaza de la Revolución	Yaima Muñoz Morejon. CENCEC
10:20	10:30	9. Micro neutralization assay for the detection of neutralizing antibodies against SARS-CoV-2.	Juliet María Enríquez Puertas. CICDC
10:30	10:40	10. Development of diagnostic capacities in the Civil Defense Scientific Research Center, to confront molecular diagnosis and vaccine and therapeutic studies against SARS-CoV-2.	Madeline Blanco de Armas. CICDC
10:40	10:50	11. Correlation between the neutralization assay and the Umelisa SARS-CoV-2 anti RBD.	Otto Cruz Sui. CICDC
10:50	11:10	Coffee Break	
11:10	11:20	12. Genetic diversity of Cuban isolates of SARS-CoV-2 used in the evaluation of therapeutic agents and vaccine candidates against COVID-19.	Liuber Yans Machado Zaldívar. CICDC
11:20	11:30	13. Development of utramicroelisas for the detection of IgG and IgM antibodies against SARS-CoV-2 in serum and plasma samples, using SUMA Technology.	Aurora Delahanty. CIE
11:30	11:40	14. Development and evaluation of an assay based on SUMA technology for the detection of the N protein of SARS-CoV-2. Application for the diagnosis of COVID-19 in Cuba.	Irinia Valdivia Alvarez. CIE
11:40	11:50	15. Preliminary results of the standardization of the real-time RT-PCR assay for the detection of the SARS-CoV-2 Envelope gene.	Yaimé Josefina González González. CIE

11:50	12:00	16. Standardization and validation of an assay based on SUMA technology for the detection of total antibodies to SARS-CoV-2.	Darien Ortega León. CIE
12:00	12:10	17. The Immunoassay Center in the fight against COVID-19	Rebeca Sonia González Fernández. CIE
12:10	12:20	18. UMEELISA® EGF: enzyme immunoassay for the determination of epidemic growth factor (EGF) in human serum samples using an ultramicroanalytical system.	Elisa María Castells Martínez. CIE
12:20	12:30	19. EGF/monocyte index: evidence on its potential as a new biomarker of inflammation.	Héctor José Pérez Hernández. Saturnino Lora Provincial Hospital, Santiago de Cuba
12:30	12:40	20. Validation of subrogated ELISA for neutralization of receptor-binding domain (RBD) binding to the ACE2 receptor with human serum or plasma samples. The assay is based on the ability of serum anti-RBD antibodies to inhibit the binding of the RBD protein to its receptor in ACE-2 cells.	Lismary Avila. CIGB
12:40	12:50	21. Vaccine candidate against SARS-CoV-2 infection. Immunogenicity and antigenicity strategic.	Mabel Izquierdo. CIGB
12:50	13:00	22. Validation of the polyacrylamide gel electrophoresis technique in the presence of SDS for the separation and control of the RBD Active Pharmaceutical Ingredient.	Osniel Cabrera Díaz. CIGB
13:00	14:30	Lunch	

Posters Board 4 (COVID-19 Symposium/Morning Session/Room 3/ Miscellaneous) Friday April 29th

Chairman: Dr. Mario Landys Chovel and Dr. Iris Valdes

9:00	9:10	1. Challenges of Cuban Biopharmaceutical Logistics in times of Covid-19	Michel Santana Garcia. ENCOMED
9:10	9:20	2. Strategies for the substitution of imports of secondary packaging material, resources and supplies, guaranteeing productive output in the confrontation with COVID-19	Michael Socorro González. BioCen
9:20	9:30	3. COVID-19 prevention strategy in the personnel of a biopharmaceutical company	Dayrene Cartaya Díaz. BioCen
9:30	9:40	4. Aspects on global health regulation for anti-COVID-19 vaccines.	Javier E. Vázquez Romero. CECMED
9:40	9:50	5. Adaptive designs in the development strategy of the SOBERANA series vaccines.	Carmen Valenzuela Silva. ICIMAF
9:50	10:00	6. The Cuban biopharmaceutical industry and Cuban medical technology in times of Covid-19. Reflection from the science of management.	Vivian Isabel Antunes Saiz. Center for the Study of Management Techniques (CETED), Havana University
10:00	10:10	7. Severity of coronavirus disease-2019 and specific antibody response to SARS-CoV-2 in convalescents from the first COVID-19 outbreak in Cuba.	Yaíma Zúñiga-Rosales. National Center of Medical Genetics
10:30	10:40	8. Clinical development strategy of the SOBERANA®02 and SOBERANA Plus vaccines for their introduction in adult and pediatric populations.	Meiby de la C. Rodríguez González. Finlay Vaccine Institute
10:10	10:20	9. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.	Beatriz Paredes. Finlay Vaccine Institute
10:20	10:30	10. Performance of the Independent Data Monitoring Committee (CIMD) in the clinical trials of the Soberana 02 and Soberana Plus vaccines, as well as the Soberana 01 vaccine candidate.	Narciso A. Jiménez Pérez. IPK
10:40	10:50	11. Immunogenicity in aged BALB/c mice of formulations with the recombinant receptor-binding domain and nucleocapsid of SARS-CoV-2 as vaccine candidates against COVID-19.	Iris Valdes. CIGB
10:50	11:10	Coffee Break	
11:10	11:20	12. Regulatory challenges for the quality control and stability evaluation of the anti-SARS-CoV-2 RBD protein-based vaccines SOBERANA 02 and SOBERANA Plus.	Mario Landys Chovel. Finlay Vaccine Institute

11:20	11:30	13. Reference materials for the quantification of anti-RBD IgG antibodies in mice sera immunized with Soberana 01, Soberana 02 y Soberana PLUS vaccines.	Lucy Herrera. Finlay Vaccine Institute
11:30	11:40	14. Comparison of the immune response of the Soberana Plus Vaccine to different routes of inoculation, response time and dose.	Juan Francisco Núñez Osenes. Finlay Vaccine Institute
11:40	11:50	15. Preliminary results of the standardization of a multiplex RT-PCR assay for the identification of mutational variants of SARS-CoV-2.	Yulaimi Batista Lozada. CIE
11:50	12:00	16. Regulatory Strategy for using Traditional and Natural Medicine for COVID-19 treatment.	Diadelis Remírez. CECMED
12:00	12:10	17. Nanoemulsión natural Curmeric® en la epidemia de COVID- 19 en Cuba.	Tania Valdés González. CEADEN
12:10	12:20	18. Management of health risks in the confrontation with COVID-19 in Cuba.	Ana Rosa Jorna Calixto. ENSP
12:20	12:30	19. Prophylactic application of nasalferon against COVID-19 in health workers. Early surveillance study.	Julio César Hernández. CIMEQ
12:30	12:40	20. Validation of the SARS-CoV-2 virus neutralization assay.	María Teresa Pérez Guevara. CICDC
12:40	12:50	21. Isolation of SARS-CoV-2 variants from Cuban patients with COVID-19.	Enrique Noa Romero. CICDC
12:50	13:00	22. Neutralizing activity of the serum of individuals immunized with the Soberana vaccine schedule against SARS-CoV-2 variants	Anitza Fraga Quintero. CICDC
13:00	14:30	Lunch	

Session/Friday April 29th

Chairman: Dra. Lilia Morales Chacón and Dr. Ariel Palenzuela

Session: Translational Research					
14:00	14:10	Lilia Morales Chacón. "Association of chronic neurological diseases with clinical phenotypes of patients with COVID-19 in intensive care units".	Center for Neurological Restoration (CIREN)	Cuba	Oral
14:15	14:25	Rafael Venegas. "Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study"	Central Military Hospital "Luis Díaz Soto"	Cuba	Oral
14:30	14:40	Vladimir Daniel Trujillo Machado. "SOBERANA Plus as a booster dose of COVID-19 vaccines"	Finlay Vaccine Institute	Cuba	Oral
14:45	14:55	Ariel Palenzuela. "Evaluation and use of UMELISA SARS-CoV-2 ANTI RBD in immunogenicity studies of individuals immunized with the Abdala and Soberana vaccines".	Immunoassay Center (CIE)	Cuba	Oral
15:00	15:10	Laura Lazo. "A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of <i>Thermothelomyces heterothallica</i> induces a functional immune response in mice"	Center for Genetic Engineering and Biotechnology (CIGB)	Cuba	Oral
15:15	15:25	Edith Suzarte. "One dose of Mambisa vaccine candidate is able to boost the immune response to SARS-CoV-2"	Center for Genetic Engineering and Biotechnology (CIGB)	Cuba	Oral
15:30	15:40	Nancy Pavón Fuentes. "Behavior of protocol adherence indicators in intensive care units. Cuba (February-July 2021)"	Center for Neurological Restoration (CIREN)	Cuba	Oral
15:45	15:55	Mireida Rodríguez Acosta. "Organizational experience of the Civil Defense Scientific Research Center in the diagnosis of COVID-19"	Civil Defense Scientific Research Center (CICDC)	Cuba	Oral